The Evaluation of Vitamin E and TiO2 Nanoparticles Administration in Parkinson’s Rat Model

Document Type : Original Article


1 Department of Molecular Cell Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran

2 Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

3 Department of Cell Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran

4 Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran


Objective: Parkinson’s disease (PD) is a severely debilitating disease for which no suitable treatment has been found
so far. In recent years, nanoparticles (NPs) have shown therapeutic potential in PD. Thus, in the current research, for
the first time, we investigated the effects of vitamin E and TiO2 nanoparticles (TiO2-NPs) on a rat model of PD.
Materials and Methods: In this experimental study, after preparation and induction of PD, rats were administrated
with vitamin E and TiO2-NPs. One day after receiving the last dose of treatments, rats were killed and substantia
nigra was extracted from the brain and its cell suspension was prepared. In each group, female rats were mated, and
after confirmation that the female rats were pregnant by vaginal smear test, the fetus was removed. Cell viability was
studied by the MTT method and apoptosis, and necrosis were studied by the flow cytometry technique. Also, after RNA
extraction and cDNA synthesis, the expression of Bcl-2 and circRNA 0001518 genes were studied using the real time
polymerase chain reaction (RT-PCR) technique. For analyzing the data, two-way ANOVA was used.
Results: The results showed a sharp decrease in cell viability in female PD rats and fetuses resulting from PD female
rats. Vitamin E treatment showed the greatest effect on increasing cell viability. Decreased expression of the Bcl-2 gene
and increased expression of circRNA 0001518 were observed in PD conditions.
Conclusion: Administration of vitamin E may be a good option for reducing PD-induced cell death.


  1. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016; 139 Suppl 1: 318-324.
  2. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990; 54(3): 823-827.
  3. Mochizuki H, Yasuda T. Iron accumulation in Parkinson’s disease. J Neural Transm (Vienna). 2012; 119(12): 1511-1514.
  4. Koutsilieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson’s disease. J Neurol. 2002; 249 Suppl 2: II1-II5.
  5. Patel M. Targeting oxidative stress in central nervous system disorders. Trends Pharmacol Sci. 2016; 37(9): 768-778.
  6. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress inducedneurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001; 40(8): 959-975.
  7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-1720.
  8. Zarei Moradi S, Angaji SA, Salehi M, Hashemi M. Impact of NiO2 nanoparticles and curcumin on testis torsion/detorsion injury: role of miR-34 and circRNA 0001518. Galen Med J. 2021; 10: e2342-e2342.
  9. Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, et al. Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. Nanoscale. 2014; 6(4): 2321-2327.
  10. Mohammad-Beigi H, Hosseini A, Adeli M, Ejtehadi MR, Christiansen G, Sahin C, et al. Mechanistic understanding of the interactions between nano-objects with different surface properties and α-synuclein. ACS Nano. 2019; 13(3): 3243-3256.
  11. Kwon HJ, Kim D, Seo K, Kim YG, Han SI, Kang T, et al. Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in parkinson’s disease. Angew Chem Int Ed Engl. 2018; 57(30): 9408-9412.
  12. Ghafoori SM, Entezari M, Taghva A, Tayebi Z. Biosynthesis and evaluation of the characteristics of silver nanoparticles using Cassia fistula fruit aqueous extract and its antibacterial activity. Adv Nat Sci: Nanosci Nanotechnol. 2017; 8(4): 045019.
  13. Wang N, Jin X, Guo D, Tong G, Zhu X. Iron chelation nanoparticles with delayed saturation as an effective therapy for Parkinson disease. Biomacromolecules. 2017; 18(2): 461-474.
  14. Bourdenx M, Daniel J, Genin E, Soria FN, Blanchard-Desce M, Bezard E, et al. Nanoparticles restore lysosomal acidification defects: implications for Parkinson and other lysosomal-related diseases. Autophagy. 2016; 12(3): 472-483.
  15. Naz S, Beach J, Heckert B, Tummala T, Pashchenko O, Banerjee T, et al. Cerium oxide nanoparticles: a ‘radical’ approach to neurodegenerative disease treatment. Nanomedicine (Lond). 2017; 12(5): 545-553.
  16. Mohammadi S, Nikkhah M. TiO2 nanoparticles as potential promoting agents of fibrillation of α-synuclein, a parkinson’s disease-related protein. Iran J Biotechnol. 2017; 15(2): 87-94.
  17. Naserzadeh P, Ghanbary F, Ashtari P, Seydi E, Ashtari K, Akbari M. Biocompatibility assessment of titanium dioxide nanoparticles in mice fetoplacental unit. J Biomed Mater Res A. 2018; 106(2): 580-589.
  18. Olivola S, Xodo S, Olivola E, Cecchini F, Londero AP, Driul L. Parkinson’s disease in pregnancy: a case report and review of the literature. Front Neurol. 2020; 10: 1349.
  19. Roghani M, Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence. Brain Res. 2001; 892(1): 211-217.
  20. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. New York: Academic Press; 1986.
  21. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Brain Res Mol Brain Res. 1996; 39(1-2): 127-136.
  22. Elabscience. Sample preparation for flow cytometry: Preparation of tissue sample. 2018; Available from: https://www.elabscience. com/List-detail-5594.html (11 Jul 2022).
  23. Apel C, Forlenza OV, de Paula VJ, Talib LL, Denecke B, Eduardo CP, et al. The neuroprotective effect of dental pulp cells in models of Alzheimer’s and Parkinson’s disease. J Neural Transm (Vienna). 2009; 116(1): 71-78.
  24. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods. 2000; 243(1-2): 167- 190.
  25. Ricciarelli R, Argellati F, Pronzato MA, Domenicotti C. Vitamin E and neurodegenerative diseases. Mol Aspects Med. 2007; 28(5-6): 591-606.
  26. Ulatowski LM, Manor D. Vitamin E and neurodegeneration. Neurobiol Dis. 2015; 84: 78-83.
  27. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a metaanalysis. Lancet Neurol. 2005; 4(6): 362-365.
  28. Fariss MW, Zhang JG. Vitamin E therapy in Parkinson’s disease. Toxicology. 2003; 189(1-2): 129-146.
  29. Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, et al. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke. 2005; 36(10): 2258-2264.
  30. Fujimoto S, Mizoi K, Yoshimoto T, Suzuki J. The protective effect of vitamin E on cerebral ischemia. Surg Neurol. 1984; 22(5): 449-454.
  31. Cederberg J, Simán CM, Eriksson UJ. Combined treatment with vitamin E and vitamin C decreases oxidative stress and improves fetal outcome in experimental diabetic pregnancy. Pediatr Res. 2001; 49(6): 755-762.
  32. Roy S, Lado BH, Khanna S, Sen CK. Vitamin E sensitive genes in the developing rat fetal brain: a high-density oligonucleotide microarray analysis. FEBS Lett. 2002; 530(1-3): 17-23.
  33. Pearson P, Lewis SA, Britton J, Young IS, Fogarty A. The prooxidant activity of high-dose vitamin E supplements in vivo. Bio- Drugs. 2006; 20(5): 271-273.
  34. Naziroglu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004; 195(2-3): 221-230.
  35. Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M, et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol. 2011; 6(5): 321-328.
  36. Moldoveanu T, Czabotar PE. BAX, BAK, and BOK: a coming of age for the BCL-2 family effector proteins. Cold Spring Harb Perspect Biol. 2020; 12(4): a036319.
  37. Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J Cell Physiol. 2019; 234(8): 14040-14049.
  38. Chen W,Schuman E. Circular RNAs in brain and other tissues: a functional enigma. Trends in Neurosciences. 2016; 39(9): 597-604.